Open access
161
Views
7
CrossRef citations to date
0
Altmetric
Original Research
Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
Jason Foo1 Global Health Economics, Mapi Group (An ICON plc Company), Houten, The NetherlandsCorrespondence[email protected]
, Mohamad Maghnie2 Department of Pediatrics, IRCCS Istituto Giannina Gaslini Institute, University of Genova, Genova, Italy
, Annamaria Colao3 Department of Clinical Medicine and Surgery, University Federico II of Naples, 80131Napoli, Italy
, Ioanna Vlachaki4 Global Health Economics, ICON plc, London, UK
& Giorgio Colombo5 Department of Drug Science, Pavia University, Pavia, Italy;6 SAVE Studi – Health Economics & Outcomes Research, Milan, Italy
https://orcid.org/0000-0002-5790-8891
Pages 525-537
|
Published online: 22 Aug 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.